scholarly journals Histological Origin and Clinicopathological Analysis of Primary Ovarian Neuroendocrine Neoplasms

2021 ◽  
Author(s):  
Yuxiang Shi ◽  
Li Li ◽  
Luyao Fan ◽  
Zheng Huang ◽  
Yonghui Xie ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Postoperative Radiotherapy ◽  
Small Cell ◽  
Neuroendocrine Cells ◽  
Transitional Epithelium ◽  
Neuroendocrine Neoplasms ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Clinicopathological Analysis ◽  
Trabecular Carcinoid

Abstract Purpose To investigate the histological origin and clinical and pathological features of primary ovarian neuroendocrine neoplasms. Methods We retrospectively analyzed nine cases of ovarian neuroendocrine neoplasms diagnosed at our hospital from January 2009 to January 2021. Results The mean age of the nine patients was 44.9 ± 15.2 years (range, 28–68 years). Six cases manifested ovarian carcinoid cancer, and the pathological types were insular and trabecular carcinoid; microscopic observation showed that the carcinoid components were limited and that stromal reaction was slight. Four cases showed teratomas, with the carcinoid components not displaying adjacent mucinous glands; and the other cases exhibited carcinoid cancer as the only tumor component, without adjacent or migratory epithelial components. The six patients were followed up for 76.6 ± 41.2 (6–123) months after resection, without disease. Two cases manifested adenocarcinoma admixed with neuroendocrine carcinoma, and the intermigration of neuroendocrine carcinoma and adenocarcinoma components could be observed; and one case was an isolated small cell neuroendocrine carcinoma with no epithelial proximity or migration observed. Adenocarcinoma admixed with neuroendocrine carcinoma and small-cell neuroendocrine carcinoma exhibited an obviously promoted interstitial reaction and damaging infiltration: these three patients underwent radical surgery supplemented by postoperative radiotherapy and chemotherapy, and follow-up lasted 34.6 ± 24.2 (7–52) months; two patients died and one showed recurrence. Conclusions Ovarian neuroendocrine neoplasms may reflect multiple tissue origins, carcinoid and simple neuroendocrine neoplasms with no adjacent, transitional epithelium, and may originate from original/transformed neuroendocrine cells or stem cells of the ovarian stroma. In addition, the adenocarcinoma admixed with neuroendocrine carcinoma may originate from dedifferentiated epithelium. The prognosis with carcinoid cancer is favorable, while the prognosis for neuroendocrine carcinoma is poor.

Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses

2006 ◽  
Vol 120 (4) ◽  
pp. 289-297 ◽  
Author(s):  
E Babin ◽  
V Rouleau ◽  
P O Vedrine ◽  
B Toussaint ◽  
D de Raucourt ◽  
...  
Keyword(s):  
Nasal Cavity ◽  
Neuroendocrine Carcinoma ◽  
Paranasal Sinuses ◽  
Neuron Specific Enolase ◽  
Current Treatment ◽  
Small Cell ◽  
Sinonasal Tract ◽  
Neuroendocrine Neoplasms ◽  
Hormone Production ◽  
Small Cell Neuroendocrine Carcinoma

Introduction: Small cell neuroendocrine carcinoma (SNEC) of the sinonasal tract is a rare disease.Objective: Report a descriptive study of a relatively large cohort of SNEC of the nasal cavity and paranasal sinuses.Method: The medical records of 21 patients presenting with nasal and paranasal SNEC to various French hospitals, from 1989 to 2003, were analysed to determine the clinical features and current treatment of the disease.Results: Patient data were obtained from eight French hospitals. Twelve of the patients were male and nine were female, with a mean age at presentation of 55 years (range: 27 to 79 years). Patients' staging for nasal cavity malignancy was: T1, four; T2, three; T3, one; T4, 13; N0, 18; N2, three; M0, 20; and M1, one. None of the patients suffered from SNEC of the sinonasal tract with ectopic hormone production. Immunohistochemistry proved useful for diagnosis in 20 cases. Twelve cases were positive for cytokeratin, 14 for chromogranin, eight for neuron-specific enolase and 11 for neuron-specific synaptophysin. One patient had an adenocarcinoma and an inverted papilloma associated with neuroendocrine carcinoma. Patients underwent surgery (11 cases), radiotherapy (14 cases) and chemotherapy (12 cases). Recurrence occurred in 10 cases. Five patients had visceral metastases or cervical lymph node involvement. Nine of the patients died within four years of onset of the disease.Conclusion: Small cell neuroendocrine carcinoma of the sinonasal tract is an uncommon neoplasm with aggressive clinical behaviour. Recurrence is frequent and the prognosis is poor. However, the current treatment of these neuroendocrine neoplasms varies widely.

Successful management of small cell neuroendocrine carcinoma of the ureter with neoadjuvant chemotherapy and adjuvant chemoradiation: case report and literature review

2021 ◽  
Vol 14 (8) ◽  
pp. e240613
Author(s):  
Mudasir Farooq ◽  
Sherin Daniel ◽  
Anjana Joel ◽  
Nirmal Thampi John
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Neuroendocrine Carcinoma ◽  
Locally Advanced ◽  
Complete Response ◽  
Small Cell ◽  
Successful Management ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Free Survival ◽  
Worse Prognosis

Neuroendocrine tumours (NETs) of the urinary tract are rare, and the urinary bladder is the the most common primary site. Primary ureteric NET is rarer with under 80 cases reported in the literature thus far. Most of these tumours are of the high-grade small cell neuroendocrine carcinoma subtype, which has a worse prognosis. Neoadjuvant chemotherapy has a proven role in the management of NET of the bladder as it downstages the tumour, which may add to significant recurrence-free survival and overall survival. We report the successful management of a patient with locally advanced small cell neuroendocrine carcinoma of the ureter, who had a pathological complete response after neoadjuvant chemotherapy with etoposide and cisplatin. He subsequently received adjuvant chemotherapy followed by radiation and is recurrence-free at a follow-up of 1 year.

Small cell neuroendocrine carcinoma of uterine cervix: The Scottish experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 15026-15026
Author(s):  
M. Siva ◽  
R. Mahmood ◽  
S. Kakumanu ◽  
A. Sadozye ◽  
N. Reed
Keyword(s):  
Overall Survival ◽  
Neuroendocrine Carcinoma ◽  
Uterine Cervix ◽  
Salvage Therapy ◽  
Total Abdominal Hysterectomy ◽  
Pelvic Lymphadenectomy ◽  
Small Cell ◽  
Therapeutic Interventions ◽  
Small Cell Neuroendocrine Carcinoma

15026 Background: Small cell neuroendocrine carcinoma (SCC) of uterine cervix is a rare sub-type of cervical cancer. We report the results of a retrospective analysis of data from 2 Scottish centres of cases of SCC of cervix. The aim is to examine therapeutic interventions, relapse patterns and survival. Methods: Eligible cases were patients (pts) with cervical SCC presented for management discussion between 1995 and 2005 in the 2 scottish centres. Pathology was reviewed centrally by the network pathologists. We reviewed pts case records for staging information, therapeutic interventions, median time to relapse, salvage therapy and responses and overall survival. Results: A total of 21 pts were eligible for the analysis (Glasgow-13 and Aberdeen-8). The median age of the pts was 33 (Range 22–74). Nine pts were FIGO stage 1B, 3 were 2A and 4 were 2B, 3 were 3B and 2 with metastatic disease. Surgery was done in 13 pts [11-radical hysterectomy/pelvic lymphadenectomy, 1-radical hyseterctomy and 1-total abdominal hysterectomy]. Chemotherapy was given to 16 pts [Neo-adjuvant-6, Adjuvant-9, Concurrent-3]. Fourteen pts received combination chemotherapy containing Platinum and Etoposide [EP-2, CE-8, ICE-1 and ACE-3]. One received non-platinum combination. Fourteen pts received radiotherapy [10-Pelvic radiotherapy and brachytherapy, 3-Pelvic only, 1-Brachytherapy only, 2-PCI]. Two pts died of progressive disease shortly after diagnosis without any specific anti-cancer treatment, two pts were disease free after a follow up of 40 and 53 months respectively and one was lost to follow up 7 yrs after diagnosis. Median relapse free survival (RFS) was 16 months. Two year RFS was 25%. The sites of relapse were as follows: Liver-4, Chest-4, Para-aortic-4, Brain-3, Neck-3, Local-2, Abdomen-1. Twelve pts received salvage therapy after relapse [5-responded, 2-not assessed and 5-progressed]. Seven pts were alive after a median follow up of 40 months [Range 17–90]. Median survival was 28 months and the three year overall survival was 45%. Conclusions: We have shown here that with combination treatment SCC can be effectively managed with occasional durable remissions. The overall survival at 3 years was 45%. We believe this was the result of aggressive combination therapy of surgery, chemo and radiotherapy. No significant financial relationships to disclose.

scholarly journals Mixed large and small cell neuroendocrine carcinoma and endometrioid carcinoma of the endometrium with high microsatellite instability: A case report and literature review

2021 ◽  
Vol 9 ◽  
pp. 2050313X2199920
Author(s):  
Kotaro Inoue ◽  
Kentaro Kai ◽  
Shimpei Sato ◽  
Haruto Nishida ◽  
Koji Hirakawa ◽  
...  
Keyword(s):  
Microsatellite Instability ◽  
Neuroendocrine Carcinoma ◽  
Immune Checkpoint Blockade ◽  
Japanese Woman ◽  
Endometrial Biopsy ◽  
Small Cell ◽  
Endometrioid Carcinoma ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Mutation Burden ◽  
Solid Part

A 65-year-old, gravida 3, para 2 Japanese woman was referred to our hospital for symptomatic thickening of the endometrial lining. Endocervical and endometrial cytology revealed an adenocarcinoma. The endometrial biopsy specimen was mixed, with a glandular part diagnosed as endometrioid carcinoma and a solid part diagnosed as high-grade mixed large and small cell neuroendocrine carcinoma (L/SCNEC). She underwent extra-fascial hysterectomy with bilateral salpingo-oophorectomy, complete pelvic and para-aortic lymphadenectomy, and omentectomy (FIGO IIIB, pT3b pN0 M0). She currently has no deleterious germline mutation, but high tumor mutation burden and high microsatellite instability (MSI) were identified. She underwent six cycles of platinum-based frontline chemotherapy and achieved complete remission. Immune checkpoint blockade therapy is a promising second-line therapy for MSI-high solid tumors. However, the MSI or mismatch repair (MMR) status of endometrial L/SCNEC remains unclear in the literature. Universal screening for MSI/MMR status is needed, particularly for a rare and aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document